Found "Digital Medicine": 195 results
Peregrine drug doubles lung cancer survival in trial
Investors cheered the news, sending shares of the drugmaker soaring 50 percent to $4.59 on the Nasdaq on Friday afternoon.The Phase 2 trial, involving 121 previously treated non-small cell lung cancer patients, found that those given a lower dose of bavituximab plus chemotherapy lived for a median o
Perceived barriers to utilise methadone maintenance therapy among male injection drug users in rural areas of southern Thailand (2015)
ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2
1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha
Parntip Juntama
Parntip Juntama is a Researcher at HITAP specializing in Health Technology Assessment (HTA) and Health Economics. Her work focuses on policy-related research that provides evidence to support healthcare policy decisions in Thailand.Research Focus:Parntip conducts research on various health policy topics to inform national public health strategies.
Panupong Chaowanasawat
Panupong Chaowanasawat is an Associate at the Health Intervention and Technology Assessment Program (HITAP). He holds a Bachelor of Science in Public Health (Honors) with a minor in Global Health and Social Medicine from Wayne State University, USA. His academic and professional background reflects a strong commitment to public health research and
OxyContin abuse down with time-release formula
(Reuters Health) – There’s more evidence that the new formulation of OxyContin, the time-release version of oxycodone, is discouraging abuse of the powerful drug.But the reformulation, introduced in August 2010 to make it harder to crush the medicine into powder, limiting the ability to snort, injec
Outcomes in Economic Evaluations of Public Health Interventions in Low- and Middle-Income Countries: Health, Capabilities and Subjective Wellbeing. (2016)
GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc
a London School of Hygiene & Tropical Medicine, London, UK
b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia
c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko
Off-label medicines: Rational or Irrational?
The use of off-label medicines is an unexplored area for healthcare priority setting, though it is common practice in countries
and can have a significant positive or negative effect on health outcomes and the efficiency of health care systems.
It is therefore important to have a rational an
Novartis argues for Glivec patent at India’s top court
(Reuters) – Swiss drugmaker Novartis told India’s top court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case that could change the rules for the country’s healthcare sector.A patent would recognize Novartis’ property rights, i
New Novartis drug shows potential in heart failure
(Reuters) – An experimental drug from Novartis may help up to half of heart failure patients for whom no effective treatment is available, although the evidence so far is indirect.Results of a mid-stage clinical trial of the drug known as LCZ696, unveiled on Sunday, gauged its effectiveness by measu
Navigating the Landscape of Digital Health: United Kingdom
Digital health technologies (DHTs) represent various products used in the healthcare system, including software, applications (apps) and online platforms benefiting individuals and the wider health and social care system. It is a field characterised by complexity and dynamism.
The English digital
10 / Page